Clinical Development Programs

We are currently conducting or have completed clinical trials of our proprietary HuCNS-SC® product candidate (purified human neural stem cells) in spinal cord injury, dry age-related macular deneneration, and in two fatal neurodegenerative disorders:

  • Spinal Cord Injury

    In December 2010, we received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial of our HuCNS-SC cells in chronic spinal cord injury. The trial initiated in March 2011 and is currently open for enrollment.  The trial is being conducted in Switzerland at the Balgrist University Hospital, University of Zurich. Learn more…

  • Pelizaeus-Merzbacher Disease (PMD)

    In November 2009, we initiated a Phase I trial of our HuCNS-SC cells in PMD, a myelination disorder that primarily affects young children.  The trial is being conducted at the University of California, San Francisco (UCSF) Benioff Children's Hospital. Learn more…

  • Dry Age-Related Macular Degeneration (AMD)

    In June, 2012 StemCells, Inc. initiated of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD) referred to as Geographic Atrophy. There are no approved treatments for dry AMD. The trial is being conducted at the Retina Foundation of the Southwest (RFSW) in Dallas, Texas, one of the leading independent vision research centers in the United States. David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, is the principal investigator of the study. Learn more…

We believe that the human safety data we are accumulating for our HuCNS-SC cells through these clinical trials will facilitate the pathway for future clinical testing in other central nervous system (CNS) disorders, including retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa.

Additional information about our clinical trials can be found at the US National Institutes of Health Clinical Trials website.

 

 

 

Back to Top

    Nalin Gupta MD, PhD, Chief of Pediatric Neurological Surgery at UCSF Benioff Children’s Hospital, performing the first transplantation of StemCells HuCNS-SC® product candidate in our Phase I PMD trial. This landmark clinical trial marks the first time that human neural stem cells have been transplanted as a potential treatment for a myelination disorder.

    Photo courtesy of UCSF

    Patient Enrollment

    We are currently screening and enrolling patients in our spinal cord injury and dry age-related macular deneration (AMD) trials.

    Learn more…

    Please Note

    You are about to open a web page or document that is hosted by a third party and is not maintained by StemCells, Inc. and to which our Privacy Policy does not apply.

    This link is provided to you for convenience and does not serve as an endorsement by StemCells, Inc. of any information or contacts that you may find on this third party site.

    Cancel | Continue

    X

    Please Note!

    You are about to open a web page or document that is hosted by a third party and is not maintained by StemCells, Inc. and to which our Privacy Policy does not apply.

    This link is provided to you for convenience and does not serve as an endorsement by StemCells, Inc. of any information or contacts that you may find on this third party site.

    Cancel | Continue

    X